Year: 2026

Conference Call to Discuss Full Year 2025 Results Scheduled for April 1, 2026 at 8:00 a.m. ET WILMINGTON, Del., March 31, 2026 (GLOBE NEWSWIRE) — Onfolio Holdings Inc. (Nasdaq: ONFO, ONFOW) (OTC: ONFOP) (“Onfolio” or the “Company”), an owner-operator of cash-generative online businesses, announces financial results for the full year ended December 31, 2025. The Company’s Annual Report on Form 10-K was filed with the Securities and Exchange Commission on March 31, 2026 and is available on the SEC’s website at www.sec.gov. Recent Corporate HighlightsSecured a $300 million convertible note financing facility in November 2025; approximately $6 million raised to date. Portfolio operating profit grew from approximately $1.4M annually in 2024 to approximately $1.8 million annually by end of 2025. EBITDA As Defined turned positive at...

Fourth Quarter 2025 vs. Fourth Quarter 2024 Revenue of $19.4 million compared to $21.8 million; Gross profit of $3.9 million compared to $4.3 million; Gross margin of 20.3% compared to 20.0%; Net income of $0.7 million compared to net income of $1.0 million; Earnings per share of $0.05 compared to earnings per share of $0.08; EBITDA(1) of $1.6 million compared to $2.3 million;Full Year 2025 vs. Full Year 2024Revenue of $69.3 million compared to $81.1 million; Gross profit of $10.6 million compared to $17.2 million; Gross margin of 15.2% (21.1% excluding A-10 Program impact) compared to 21.3%; Net (loss) income of ($0.8) million compared to net income of $3.3 million; (Loss) earnings per share of ($0.07) compared to earnings per share of $0.26; Adjusted EBITDA(1) of $1.0 million ($5.5 million excluding A-10 Program impact) compared...

Transformational Juniper Merger Drives Step-Change in Scale, Reserves and Earnings Power HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) — PEDEVCO Corp. (NYSE American: PED) (“PEDEVCO” or the “Company”), a publicly traded energy company engaged in the acquisition and development of strategic oil and gas assets in the Rocky Mountain region, today reported audited financial results for the fourth quarter and full year ended December 31, 2025. The Company’s full year 2025 results reflect the closing of its transformative merger with certain portfolio companies controlled by Juniper Capital Advisors, L.P. (the “Juniper Merger”) on October 31, 2025, with the consolidated financial results for the year ended December 31, 2025 including only two months of contribution from the acquired assets. The fourth quarter of 2025 similarly reflects a partial-quarter...

Shareholders approve acquisition of Aptose by Hanmi Pharmaceutical in “Go Private” transaction  TUS+VEN+AZA triplet frontline therapy continues to demonstrate favorable safety and high rates of efficacy and MRD-negative remissions in newly diagnosed AML patients with diverse mutationsSAN DIEGO and TORONTO, March 31, 2026 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today provided a corporate update and announced the financial results for the year ended December 31, 2025. “We are pleased that shareholders have approved our proposed arrangement with Hanmi, which enables us to continue and expand the...

– Grew Total Revenue 11% Year-over-Year to $187.1 Million – – Assets Under Management (“AuM”) Increased 11% Year-over-Year to $29.9 Billion – – Net Income of $2.3 Million – – Increased EBITDA[*] to $5.4 Million from $2.0 Million in the Prior Year – NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) — Binah Capital Group, Inc. (“Binah”, “Binah Capital” or the “Company”) (NASDAQ: BCG; BCGWW), a leading financial services enterprise that owns and operates a network of industry-leading firms empowering independent financial advisors, today announced results for the quarter and full year ended December 31, 2025. “We completed our first full year as a public company with strong results in the fourth quarter, which reflects the continuing growth of our differentiated platform,” stated Craig Gould, Chief Executive Officer of Binah Capital Group....

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW CALGARY, Alberta, March 31, 2026 (GLOBE NEWSWIRE) — High Arctic Energy Services Inc. (TSX: HWO) (the “Corporation” or “High Arctic”) released its fourth quarter and annual financial and operating results for the year ended December 31, 2025. The audited consolidated financial statements (the “Financial Statements”), management discussion & analysis (“MD&A”), and annual information form (“AIF”) for the year ended December 31, 2025 will be available on SEDAR+ at www.sedarplus.ca, and on High Arctic’s website at www.haes.ca. All amounts are denominated in thousands of Canadian dollars (“CAD”), unless otherwise indicated. Lonn Bate, Interim Chief...

TORONTO, March 31, 2026 (GLOBE NEWSWIRE) — Allied Gold Corporation (TSX: AAUC) (NYSE: AAUC) (“Allied” or the “Company”) herein provides its audited financial and operational results for the fourth quarter of 2025. As previously disclosed, the Company produced 117,004 ounces of gold in the fourth quarter and 379,081 ounces for the full-year 2025. Performance was in line with expectations and operating plans, exceeding Q4 guidance and delivering solid momentum heading into 2026. All-in Sustaining Costs (“AISC”)(1) for the quarter improved from the previous period and are estimated at $1,980 per ounce sold, which, together with higher realized gold prices, led to increased margins and cash flows. FOURTH QUARTER HIGHLIGHTS Financial Results HighlightsEarnings:Fourth quarter net loss of $23.6 million or $(0.19) per share. Fourth...

MIRAMAR, Fla., March 31, 2026 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation, today reported financial results and recent business highlights for its three months ended December 31, 2025. On November 17, 2025, the Company initiated its first-in-human clinical trial to evaluate HCW9302, the lead product candidate for the Company’s program to develop treatments for autoimmune disorders and proinflammatory diseases, in patients with areata alopecia. HCW9302 is a subcutaneously injectable, first-in-kind interleukin-2 (“IL-2”) fusion immunotherapeutic. IL-2, the active component of HCW9302, is the cytokine in humans and other vertebrates...